UPM Says Proposed Remedies Support Ongoing Review Process
UPM says proposed remedies were offered to support the ongoing review process and do not change its view that the transaction raises no competition concerns.
Related stories
Adani Ports selected to buy 100% stake in EVOS B.V.
M impact | MNA | Nov 05, 2026, 09:40 AM UTC
Sappi, UPM Offer Remedies to Seek EU Approval for Paper JV
Sappi and UPM have offered remedies in a bid to secure EU antitrust approval for their paper joint venture.
L impact | MNA | Nov 05, 2026, 09:15 AM UTC
AstraZeneca Makes About $10 Billion Offer for Rhythm Pharmaceuticals
AstraZeneca has made an offer of about $10 billion for Rhythm Pharmaceuticals, MT Newswires reports.
M impact | MNA | Nov 05, 2026, 09:07 AM UTC
Air France-KLM Hopes to Complete SAS Deal by Q1 2027
Air France-KLM’s CEO said the company hopes to complete its deal for SAS by Q1 2027.
L impact | MNA | Nov 05, 2026, 09:04 AM UTC
Total Graphite announces acquisition and £0.41m CLN fundraise
M impact | MNA | Nov 05, 2026, 09:00 AM UTC
BL Pharmtech Agrees to Sell 13.96% Stake in Kwangdong Healthbio
BL Pharmtech agreed to sell a 13.96% stake in Kwangdong Healthbio.
M impact | MNA | Nov 05, 2026, 08:58 AM UTC